Ionis Shares Get Price Target Lift After Tryngolza FDA Nod
H.C. Wainwright raises Ionis Pharmaceuticals' price target to $130 following FDA approval of its RNA-targeted therapy Tryngolza. H.C. Wainwright increased its price target on Ionis Pharmaceuticals (NASDAQ:IONS) to $130 from $125, maintaining a Buy rating. The adjustment fo